Routine cases reported within 10-14 days. Expedited cases will be reported within 7 days upon request.
Additional Information
FLT3 is a receptor tyrosine kinase expressed on the surface of many types of hematopoietic stem and progenitor cells. It is mutated in approximately one-third of AML patients. Internal tandem in frame duplications (ITD) within its cytoplasmic domain lead to its constitutive activation. ITD mutations represent the most common type of FLT3 mutations and occur in approximately 23% of adult AML cases. Another FLT3 mutation, termed D835, consists of an amino acid substitution in the FLT3 kinase domain and is found in approximately 12% of AML cases. Cytogenetically normal AML without the FLT3-ITD mutation constitutes a more favorable outcome than cytogenetically normal AML with a FLT3-ITD mutation.
This test will determine the presence or absence of the FLT3 ITD and D835 mutations. In addition, it will report the ratio of mutant to normal ITD alleles, which can be used as a guide for the combination treatment of FLT3-positive AML with chemotherapy and the multikinase inhibitor midostaurin.
This test was developed and its performance characteristics determined by the UCSF Clinical Laboratories. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.
Reflex Testing
An interpretation of this test by a laboratory physician will automatically be performed and billed for separately.
Synonyms
FLT-3
fms-related tyrosine kinase 3
fetal liver kinase-2
FLT3-ITD
FLT3-D835
Sample Type
Blood, bone marrow aspirate, FFPE sections
Collect
Lavender top (EDTA)
Amount to Collect
See Preferred Volume
Preferred Volume
Blood: 5 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x5 on uncharged, unstained, glass slides plus one H&E stained section
Minimum Volume
Blood: 2 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x3 on uncharged, unstained, glass slides plus one H&E stained section
Remarks
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Stability (from collection to initiation)
Room temperature 3 days, refrigerated 1 week, frozen unacceptable.
Test Code
FLT3
Test Group
AML molecular markers
Performing Lab
Medical Genomics - Molecular Diagnostics
Specimen Preparation
Do not freeze blood or bone marrow samples. Ship to CB as soon as possible.
Preferred Volume
Blood: 5 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x5 on uncharged, unstained, glass slides plus one H&E stained section
Minimum Volume
Blood: 2 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x3 on uncharged, unstained, glass slides plus one H&E stained section
Stability (from collection to initiation)
Room temperature 3 days, refrigerated 1 week, frozen unacceptable.
Reference Interval
Negative
Additional Information
FLT3 is a receptor tyrosine kinase expressed on the surface of many types of hematopoietic stem and progenitor cells. It is mutated in approximately one-third of AML patients. Internal tandem in frame duplications (ITD) within its cytoplasmic domain lead to its constitutive activation. ITD mutations represent the most common type of FLT3 mutations and occur in approximately 23% of adult AML cases. Another FLT3 mutation, termed D835, consists of an amino acid substitution in the FLT3 kinase domain and is found in approximately 12% of AML cases. Cytogenetically normal AML without the FLT3-ITD mutation constitutes a more favorable outcome than cytogenetically normal AML with a FLT3-ITD mutation.
This test will determine the presence or absence of the FLT3 ITD and D835 mutations. In addition, it will report the ratio of mutant to normal ITD alleles, which can be used as a guide for the combination treatment of FLT3-positive AML with chemotherapy and the multikinase inhibitor midostaurin.
This test was developed and its performance characteristics determined by the UCSF Clinical Laboratories. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Collect
Lavender top (EDTA)
Amount to Collect
See Preferred Volume
Sample Type
Blood, bone marrow aspirate, FFPE sections
Preferred Volume
Blood: 5 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x5 on uncharged, unstained, glass slides plus one H&E stained section
Minimum Volume
Blood: 2 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x3 on uncharged, unstained, glass slides plus one H&E stained section
Specimen Preparation
Do not freeze blood or bone marrow samples. Ship to CB as soon as possible.
Reference Interval
Negative
Synonyms
FLT-3
fms-related tyrosine kinase 3
fetal liver kinase-2
FLT3-ITD
FLT3-D835
Stability (from collection to initiation)
Room temperature 3 days, refrigerated 1 week, frozen unacceptable.
Reported
Routine cases reported within 10-14 days. Expedited cases will be reported within 7 days upon request.
Reflex Testing
An interpretation of this test by a laboratory physician will automatically be performed and billed for separately.
Additional Information
FLT3 is a receptor tyrosine kinase expressed on the surface of many types of hematopoietic stem and progenitor cells. It is mutated in approximately one-third of AML patients. Internal tandem in frame duplications (ITD) within its cytoplasmic domain lead to its constitutive activation. ITD mutations represent the most common type of FLT3 mutations and occur in approximately 23% of adult AML cases. Another FLT3 mutation, termed D835, consists of an amino acid substitution in the FLT3 kinase domain and is found in approximately 12% of AML cases. Cytogenetically normal AML without the FLT3-ITD mutation constitutes a more favorable outcome than cytogenetically normal AML with a FLT3-ITD mutation.
This test will determine the presence or absence of the FLT3 ITD and D835 mutations. In addition, it will report the ratio of mutant to normal ITD alleles, which can be used as a guide for the combination treatment of FLT3-positive AML with chemotherapy and the multikinase inhibitor midostaurin.
This test was developed and its performance characteristics determined by the UCSF Clinical Laboratories. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.
Routine cases reported within 10-14 days. Expedited cases will be reported within 7 days upon request.
Additional Information
FLT3 is a receptor tyrosine kinase expressed on the surface of many types of hematopoietic stem and progenitor cells. It is mutated in approximately one-third of AML patients. Internal tandem in frame duplications (ITD) within its cytoplasmic domain lead to its constitutive activation. ITD mutations represent the most common type of FLT3 mutations and occur in approximately 23% of adult AML cases. Another FLT3 mutation, termed D835, consists of an amino acid substitution in the FLT3 kinase domain and is found in approximately 12% of AML cases. Cytogenetically normal AML without the FLT3-ITD mutation constitutes a more favorable outcome than cytogenetically normal AML with a FLT3-ITD mutation.
This test will determine the presence or absence of the FLT3 ITD and D835 mutations. In addition, it will report the ratio of mutant to normal ITD alleles, which can be used as a guide for the combination treatment of FLT3-positive AML with chemotherapy and the multikinase inhibitor midostaurin.
This test was developed and its performance characteristics determined by the UCSF Clinical Laboratories. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.
Reflex Testing
An interpretation of this test by a laboratory physician will automatically be performed and billed for separately.
Synonyms
FLT-3
fms-related tyrosine kinase 3
fetal liver kinase-2
FLT3-ITD
FLT3-D835
Collection
Sample Type
Blood, bone marrow aspirate, FFPE sections
Collect
Lavender top (EDTA)
Amount to Collect
See Preferred Volume
Preferred Volume
Blood: 5 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x5 on uncharged, unstained, glass slides plus one H&E stained section
Minimum Volume
Blood: 2 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x3 on uncharged, unstained, glass slides plus one H&E stained section
Remarks
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Stability (from collection to initiation)
Room temperature 3 days, refrigerated 1 week, frozen unacceptable.
Processing
Test Code
FLT3
Test Group
AML molecular markers
Performing Lab
Medical Genomics - Molecular Diagnostics
Specimen Preparation
Do not freeze blood or bone marrow samples. Ship to CB as soon as possible.
Preferred Volume
Blood: 5 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x5 on uncharged, unstained, glass slides plus one H&E stained section
Minimum Volume
Blood: 2 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x3 on uncharged, unstained, glass slides plus one H&E stained section
Stability (from collection to initiation)
Room temperature 3 days, refrigerated 1 week, frozen unacceptable.
Result Interpretation
Reference Interval
Negative
Additional Information
FLT3 is a receptor tyrosine kinase expressed on the surface of many types of hematopoietic stem and progenitor cells. It is mutated in approximately one-third of AML patients. Internal tandem in frame duplications (ITD) within its cytoplasmic domain lead to its constitutive activation. ITD mutations represent the most common type of FLT3 mutations and occur in approximately 23% of adult AML cases. Another FLT3 mutation, termed D835, consists of an amino acid substitution in the FLT3 kinase domain and is found in approximately 12% of AML cases. Cytogenetically normal AML without the FLT3-ITD mutation constitutes a more favorable outcome than cytogenetically normal AML with a FLT3-ITD mutation.
This test will determine the presence or absence of the FLT3 ITD and D835 mutations. In addition, it will report the ratio of mutant to normal ITD alleles, which can be used as a guide for the combination treatment of FLT3-positive AML with chemotherapy and the multikinase inhibitor midostaurin.
This test was developed and its performance characteristics determined by the UCSF Clinical Laboratories. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
Collect
Lavender top (EDTA)
Amount to Collect
See Preferred Volume
Sample Type
Blood, bone marrow aspirate, FFPE sections
Preferred Volume
Blood: 5 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x5 on uncharged, unstained, glass slides plus one H&E stained section
Minimum Volume
Blood: 2 mL
Bone marrow aspirate: 3 mL
?FFPE: 10 micron sections x3 on uncharged, unstained, glass slides plus one H&E stained section
Specimen Preparation
Do not freeze blood or bone marrow samples. Ship to CB as soon as possible.
Reference Interval
Negative
Synonyms
FLT-3
fms-related tyrosine kinase 3
fetal liver kinase-2
FLT3-ITD
FLT3-D835
Stability (from collection to initiation)
Room temperature 3 days, refrigerated 1 week, frozen unacceptable.
Reported
Routine cases reported within 10-14 days. Expedited cases will be reported within 7 days upon request.
Reflex Testing
An interpretation of this test by a laboratory physician will automatically be performed and billed for separately.
Additional Information
FLT3 is a receptor tyrosine kinase expressed on the surface of many types of hematopoietic stem and progenitor cells. It is mutated in approximately one-third of AML patients. Internal tandem in frame duplications (ITD) within its cytoplasmic domain lead to its constitutive activation. ITD mutations represent the most common type of FLT3 mutations and occur in approximately 23% of adult AML cases. Another FLT3 mutation, termed D835, consists of an amino acid substitution in the FLT3 kinase domain and is found in approximately 12% of AML cases. Cytogenetically normal AML without the FLT3-ITD mutation constitutes a more favorable outcome than cytogenetically normal AML with a FLT3-ITD mutation.
This test will determine the presence or absence of the FLT3 ITD and D835 mutations. In addition, it will report the ratio of mutant to normal ITD alleles, which can be used as a guide for the combination treatment of FLT3-positive AML with chemotherapy and the multikinase inhibitor midostaurin.
This test was developed and its performance characteristics determined by the UCSF Clinical Laboratories. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.
